McCarter Private Wealth Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.1M Sell
6,249
-430
-6% -$191K 1.07% 32
2026
Q1
$2.98M Buy
6,679
+442
+7% +$206K 1.3% 21
2025
Q4
$2.83M Buy
6,237
+188
+3% +$81K 1.27% 23
2025
Q3
$2.37M Sell
6,049
-24
-0.4% -$10K 1.21% 27
2025
Q2
$2.7M Sell
6,073
-75
-1% -$34.6K 1.55% 24
2025
Q1
$2.98M Sell
6,148
-35
-0.6% -$16.3K 1.95% 18
2024
Q4
$2.49M Buy
6,183
+49
+0.8% +$22.7K 1.58% 21
2024
Q3
$2.85M Buy
+6,134
New +$2.95M 1.8% 20

Other funds holding VRTX

McCarter Private Wealth Services's VRTX Position: Q2 2026 in Review

McCarter Private Wealth Services reduced its Vertex Pharmaceuticals (VRTX) stake by 6.4% in Q2 2026, selling an estimated $191K and leaving 6,249 shares worth $3.1M. The position accounts for 1.07% of the portfolio, ranked #32.

McCarter Private Wealth Services first reported a position in VRTX in Q3 2024 and has held it in 8 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • McCarter Private Wealth Services held 6,249 shares of Vertex Pharmaceuticals worth $3.1M as of Q2 2026.
  • McCarter Private Wealth Services sold 430 Vertex Pharmaceuticals shares in Q2 2026, an estimated $191K.
  • Vertex Pharmaceuticals made up 1.07% of McCarter Private Wealth Services's portfolio in Q2 2026, its #32 holding.
  • McCarter Private Wealth Services first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on McCarter Private Wealth Services's 13F filing for Q2 2026, filed 5 Aug 2026.